Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

NCT04874714 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

18

Enrollment

INDUSTRY

Sponsor class

Stopped Due to the low recruitment rate since the start of the trial

Conditions

Allergic Rhinoconjunctivitis
Perennial Allergic Rhinitis
House Dust Mite Allergy
Pollen Allergy

Interventions

BIOLOGICAL: MM09-MG01(30.000-30.000)
BIOLOGICAL: MG01(30.000)
BIOLOGICAL: MM09(30.000)
BIOLOGICAL: Placebo subcutaneous

Sponsor

Inmunotek S.L.

Collaborators

[object Object]
[object Object]